175 related articles for article (PubMed ID: 35120091)
1. Current and emerging immunotherapies for recurrent cervical cancer.
Liu MC; Tewari KS
Clin Adv Hematol Oncol; 2022 Feb; 20(2):108-115. PubMed ID: 35120091
[TBL] [Abstract][Full Text] [Related]
2. Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.
Bose CK
Med Oncol; 2022 Jan; 39(4):47. PubMed ID: 35092506
[TBL] [Abstract][Full Text] [Related]
3. Advances in immunotherapy for cervical cancer.
Wendel Naumann R; Leath CA
Curr Opin Oncol; 2020 Sep; 32(5):481-487. PubMed ID: 32740092
[TBL] [Abstract][Full Text] [Related]
4. IMMUNOTHERAPY TREATMENT AGAINST CERVICAL CANCER.
Jiménez-Lima R; Arango-Bravo E; Galicia-Carmona T; Lino-Silva LS; Trejo-Durán GE; Alvarado-Silva C; Castañeda-Renderos OH; Vanoye-Carlo EG; Torre CF; Dueñas-González A; Cetina-Pérez L
Rev Invest Clin; 2020; 72(4):231-238. PubMed ID: 33064705
[TBL] [Abstract][Full Text] [Related]
5. RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.
O'Malley DM; Randall LM; Jackson CG; Coleman RL; Hays JL; Moore KN; Naumann RW; Rocconi RP; Slomovitz BM; Tewari KS; Ancukiewicz M; Feliu WO; Monk BJ
Future Oncol; 2021 Sep; 17(26):3433-3443. PubMed ID: 34409858
[TBL] [Abstract][Full Text] [Related]
6. Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials.
Monk BJ; Enomoto T; Kast WM; McCormack M; Tan DSP; Wu X; González-Martín A
Cancer Treat Rev; 2022 May; 106():102385. PubMed ID: 35413489
[TBL] [Abstract][Full Text] [Related]
7. EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer.
Oaknin A; Monk BJ; Vergote I; Cristina de Melo A; Kim YM; Lisyanskaya AS; Samouëlian V; Kim HS; Gotovkin EA; Damian F; Chang CL; Takahashi S; Li J; Mathias M; Fury MG; Ivanescu C; Reaney M; LaFontaine PR; Lowy I; Harnett J; Chen CI; Tewari KS
Eur J Cancer; 2022 Oct; 174():299-309. PubMed ID: 35922251
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
9. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
10. Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy.
Cohen AC; Roane BM; Leath CA
Drugs; 2020 Feb; 80(3):217-227. PubMed ID: 31939072
[TBL] [Abstract][Full Text] [Related]
11. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
[TBL] [Abstract][Full Text] [Related]
12. Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update.
Verhoeven Y; Quatannens D; Trinh XB; Wouters A; Smits ELJ; Lardon F; De Waele J; van Dam PA
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670397
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in melanoma: Recent advances and future directions.
Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
15. Tisotumab vedotin in recurrent or metastatic cervical cancer.
Bogani G; Coleman RL; Vergote I; Raspagliesi F; Lorusso D; Monk BJ
Curr Probl Cancer; 2023 Jun; 47(3):100952. PubMed ID: 36842202
[TBL] [Abstract][Full Text] [Related]
16. Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience.
Indini A; Di Guardo L; Cimminiello C; Lorusso D; Raspagliesi F; Del Vecchio M
J Gynecol Oncol; 2019 Nov; 30(6):e94. PubMed ID: 31576688
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
Grau JF; Farinas-Madrid L; Oaknin A
Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
[TBL] [Abstract][Full Text] [Related]
18. Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey.
Richardson MT; Attwood K; Smith G; Liang SY; LaVigne Mager K; Tewari KS; Coleman RL; Kapp DS; Chan JK; Monk BJ
Cancer Control; 2023; 30():10732748231182795. PubMed ID: 37646470
[TBL] [Abstract][Full Text] [Related]
19. Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.
Dyer BA; Zamarin D; Eskandar RN; Mayadev JM
J Natl Compr Canc Netw; 2019 Jan; 17(1):91-97. PubMed ID: 30659133
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab for the treatment of cervical cancer.
Marret G; Borcoman E; Le Tourneau C
Expert Opin Biol Ther; 2019 Sep; 19(9):871-877. PubMed ID: 31322926
[No Abstract] [Full Text] [Related]
[Next] [New Search]
